Recurrent Small Cell Lung Cancer (SCLC) Recruiting Phase 2 Trials for Metformin (DB00331)

Back to Recurrent Small Cell Lung Cancer (SCLC)

Also known as: Recurrent Small-cell Lung Cancer (SCLC) / Recurrent Small Cell Lung Cancer / Refractory Small cell lung cancer / Small Cell Lung Cancer Recurrent

IndicationStatusPhase
DBCOND0122754 (Recurrent Small Cell Lung Cancer (SCLC))Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03994744Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLCTreatment